Latest News On Drug Costs

Latest California Healthline Stories

KFF Health News' 'What the Health?': Health Funding in Question in a Speaker-Less Congress

A bitterly divided Congress managed to keep the federal government running for several more weeks, while House Republicans struggle — again — to choose a leader. Meanwhile, many people removed from state Medicaid rolls are not finding their way to Affordable Care Act insurance, and a major investigation by The Washington Post attributes the decline in U.S. life expectancy to more than covid-19 and opioids. Lauren Weber of The Washington Post, Victoria Knight of Axios, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews physician-author-playwright Samuel Shem about “Our Hospital,” his new novel about the health workforce in the age of covid.

KFF Health News' 'What the Health?': Countdown to Shutdown

Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.

Resurge la hepatitis C, ¿podrá el plan de Biden eliminar este viejo flagelo en cinco años?

Se calcula que el 40% de los más de 2 millones de personas con hepatitis C en Estados Unidos ni siquiera saben que la tienen, pero el virus puede estar dañando silenciosamente su hígado, causando cicatrices, insuficiencia hepática o cáncer de hígado.

Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice

Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.

KFF Health News' 'What the Health?': Welcome Back, Congress. Now Get to Work. 

Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.

A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?